Future directions for precision oncology in prostate cancer

Area of Science:

• Oncology
• Genomics
• Biotechnology

Background:

• Clinical genomic testing is increasingly standard for prostate cancer, guiding therapies like PARP inhibitors and immunotherapy for specific patients.
• Challenges remain in precision medicine for prostate cancer, including the low prevalence of actionable genomic alterations and incomplete understanding of tumor heterogeneity's impact on treatment outcomes.

Purpose of the Study:

• To review recent technological advancements in precision oncology for advanced prostate cancer.
• To explore how novel tissue-based, blood-based, and molecular imaging technologies can enhance the understanding and application of precision medicine.

Main Methods:

• Review of current literature on advanced genomic and molecular profiling technologies.
• Discussion of emerging tissue-based (whole-genome sequencing, single-cell RNA sequencing), blood-based (ctDNA, CTCs, EVs), and molecular imaging techniques.

Main Results:

• Expanded tissue-based analyses (e.g., whole-genome sequencing) and less invasive blood-based methods (e.g., cell-free DNA) offer potential to capture tumor heterogeneity and track treatment response.
• Molecular imaging can non-invasively detect heterogeneity across metastases and identify therapeutic targets.

Conclusions:

• Technological advances in genomic testing, liquid biopsies, and molecular imaging are crucial for advancing precision oncology in advanced prostate cancer.
• These innovations hold the potential to overcome current challenges and improve treatment strategies for diverse patient populations.